



Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

Ohsang Kwon¹ · Maryanne M. Senna² · Rodney Sinclair³ · Taisuke Ito⁴ · Yves Dutronc⁵ · Chen-Yen Lin⁵ · Guanglei Yu⁵ · Chiara Chiasserini⁵ · Jill McCollam⁵ · Wen-Shuo Wu⁵ · Brett King⁶

Accepted: 20 February 2023

© The Author(s) 2023

Abstract

Background The oral Janus kinase (JAK) inhibitor baricitinib has demonstrated efficacy for severe alopecia areata (AA) over 36 weeks. There are limited data on the longer-term treatment of AA.

Objective The aim of this study was to evaluate the efficacy and safety of baricitinib for AA in adults with $\geq 50\%$ scalp hair loss through 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2).

Methods Patients randomized to baricitinib at baseline in BRAVE-AA1 ($N = 465$) and BRAVE-AA2 ($N = 390$) retained their treatment allocation through Week 52. Efficacy outcomes included the proportion of patients achieving a Severity of Alopecia Tool (SALT) score ≤ 20 ($\leq 20\%$ scalp hair loss). Data were censored after permanent treatment discontinuation or if collected remotely due to the coronavirus disease 2019 (COVID-19) pandemic.

Results Response rates for hair regrowth increased over the 52-week period. Of patients treated with baricitinib 4 mg and 2 mg, respectively, 40.9% and 21.2% in BRAVE-AA1 and 36.8% and 24.4% in BRAVE-AA2 achieved a SALT score ≤ 20 at Week 52. The most frequent treatment-emergent adverse events included upper respiratory tract infection, headache, nasopharyngitis, acne, urinary tract infection, creatine phosphokinase elevation, and COVID-19 infection.

Limitation There were no comparisons with placebo.

Conclusion Efficacy of baricitinib for adults with severe AA continuously improved over 52 weeks, indicating that long-term treatment may be necessary to observe maximum clinical benefit. There were no new safety signals.

ClinicalTrials Registration ClinicalTrials.gov NCT03570749 and NCT03899259.

Plain Language Summary

Alopecia areata (AA) is an autoimmune disease that causes patchy hair loss on the scalp, face, and body. Baricitinib is a Janus kinase inhibitor that is approved to treat AA in several countries, based on results from two studies, BRAVE-AA1 and BRAVE-AA2. In these studies, adults with at least 50% scalp hair loss were treated with baricitinib for 36 weeks. Long-term therapy is important in AA, and hair regrowth can take longer in some patients with severe disease. Therefore, we assessed outcomes from a longer course of therapy. In this study, we report the results after 52 weeks of continuous treatment with baricitinib 4 mg or 2 mg in 465 patients in BRAVE-AA1 and 390 patients BRAVE-AA2. The goal was to reduce scalp hair loss to 20% or less by Week 52. In BRAVE-AA1, 40.9% of patients who took baricitinib 4 mg and 21.2% of patients who took baricitinib 2 mg had 20% or less missing scalp hair by Week 52. Similarly, in BRAVE-AA2, 36.8% of patients who

✉ Ohsang Kwon
oskwon@snu.ac.kr

¹ Department of Dermatology, Seoul National University College of Medicine, 103 Daehak-ro, Ihwa-dong, Jongno-gu, Seoul 03080, Republic of Korea

² Division of Dermatology, Lahey Hospital and Medical Center, and Harvard Medical School, Boston, MA, USA

³ Sinclair Dermatology, Melbourne, VIC, Australia

⁴ Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan

⁵ Eli Lilly and Company, Indianapolis, IN, USA

⁶ Yale School of Medicine, New Haven, CT, USA

took baricitinib 4 mg and 24.4% of patients who took baricitinib 2 mg had 20% or less missing scalp hair by Week 52. The most common adverse effects that were reported during the study period were upper respiratory tract infection, headache, nasopharyngitis, acne, urinary tract infection, creatine phosphokinase elevation, and coronavirus disease 2019 (COVID-19) infection. The results of longer-term treatment indicate that hair regrowth continues to improve without any new safety concerns for adults with severe AA taking baricitinib.

Digital Features for this article can be found at <https://doi.org/10.6084/m9.figshare.22129661>.

Key Points

The oral Janus kinase inhibitor baricitinib has demonstrated efficacy for adults with severe alopecia areata ($\geq 50\%$ scalp hair loss) over 36 weeks.

In two phase III trials, efficacy of baricitinib for severe alopecia areata continued to improve over 52 weeks.

1 Introduction

Alopecia areata (AA) is an autoimmune disorder causing non-scarring hair loss on the scalp, face, and body. Severe AA ($\geq 50\%$ scalp hair loss) is unlikely to remit without treatment, with only 3.3–6.2% of patients achieving $\geq 80\%$ scalp hair coverage with placebo in recent 36-week trials [1].

Clinical studies indicate Janus kinase (JAK) inhibitors may interrupt inflammatory pathways that contribute to the immunopathogenesis of AA [2–4]. The oral, selective, and reversible JAK1/JAK2 inhibitor baricitinib is the first FDA-approved treatment for adults with severe AA and is in late-stage development for pediatric patients with severe AA. There are limited data on longer-term outcomes with oral JAK inhibitors in large cohorts of patients with severe AA.

In two phase III randomized trials of adults with severe AA, baricitinib was superior to placebo in hair regrowth over 36 weeks of treatment [1]. Using data from the long-term extension periods of BRAVE-AA1 and BRAVE-AA2, we report the efficacy and safety of baricitinib 4 mg and 2 mg over 52 weeks of continuous therapy.

2 Methods

2.1 Patients and Study Design

BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259) are ongoing, independent, randomized, double-blind, parallel-group, placebo-controlled studies

evaluating the efficacy and safety of baricitinib for AA. Eligibility criteria were detailed previously [1]. Patients included adults who had a Severity of Alopecia Tool (SALT) score ≥ 50 ($\geq 50\%$ scalp hair loss) and a current AA episode lasting > 6 months to < 8 years without spontaneous improvement (i.e., no more than 10-point SALT score reduction) over the 6 months prior to screening.

The trials had identical design for the first 52 weeks. Patients were randomized 2:2:3 to receive once-daily oral placebo, baricitinib 2 mg, or baricitinib 4 mg for 36 weeks. All patients who completed the 36-week placebo-controlled period entered an extension phase, for up to 68 weeks of additional treatment. At Week 36, placebo non-responders (SALT score > 20) were rescued to baricitinib, while placebo responders (SALT score ≤ 20) remained on placebo through Week 52. The present analyses focus on patients randomized to either of the baricitinib doses at baseline, who retained their treatment allocation through Week 52 regardless of response at Week 36. Patients and investigators remained blinded to treatment assignment.

First and last patients, respectively, entered treatment in March 2019 and June 2020 in BRAVE-AA1 and July 2019 and May 2020 in BRAVE-AA2. The trials were conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The research protocols were approved by each center's Institutional Review Board (IRB) or Ethics Committee. All patients provided written informed consent.

2.2 Endpoints

Efficacy outcomes at 52 weeks included the proportion of patients achieving SALT score ≤ 20 ($\leq 20\%$ scalp hair loss), which is considered a clinically meaningful outcome for patients with $\geq 50\%$ scalp hair loss at baseline [5]. The SALT score is a weighted sum of percentage hair loss in four areas of the scalp, ranging from 0 (no hair loss) to 100 (complete hair loss) [6]. Other endpoints included the percentage change from baseline in SALT score, the proportions of patients achieving $\geq 50\%$ and $\geq 90\%$ improvements from baseline in SALT score (SALT₅₀ and SALT₉₀, respectively), and the proportion achieving a SALT score ≤ 10 ($\leq 10\%$ scalp hair loss). Also assessed were the proportion of patients achieving Clinician-Reported Outcome (ClinRO) Measure for Eyebrow Hair Loss™ 0 or 1 (full

coverage or minimal gaps) with ≥ 2 -point improvement from baseline among patients with baseline scores of 2 or 3 (significant gaps or no notable eyebrows) and the proportion achieving ClinRO Measure for Eyelash Hair Loss™ 0 or 1 (no or minimal gaps) with ≥ 2 -point improvement from baseline among patients with baseline scores of 2 or 3 (significant gaps or no notable eyelashes) [7].

Safety assessments included adverse events (AEs), serious AEs (SAEs), and clinical laboratory tests. An independent data and safety monitoring committee periodically reviewed unblinded efficacy and safety data. Deaths, major adverse cardiovascular events (MACEs), and arterial (ATEs) and venous thromboembolic events (VTEs) were adjudicated by an independent blinded clinical endpoint committee.

2.3 Statistical Analysis

Efficacy analysis included all patients randomized to baricitinib at baseline (intention-to-treat analysis). Data were censored after permanent study drug discontinuation or if collected remotely due to the coronavirus disease 2019 (COVID-19) pandemic. For categorical outcomes, non-responder imputation was applied to missing and censored data. For continuous outcomes, missing and censored data were imputed with modified last observation carried forward, using the most recent non-missing post-baseline assessment. Results from these prespecified analyses are presented below. Placebo-controlled outcomes at Week 36 were previously reported with both the prespecified analyses and with multiple imputation applied to missing data [1]; Week-52 results using multiple imputation are available in the electronic supplementary material (ESM) for comparison with the Week 36 results. Differences in outcomes between baricitinib doses were not analyzed.

Safety analysis included all patients randomized to baricitinib at baseline who received one or more doses of study drug and who did not discontinue for the reason ‘lost to follow-up’ at first post-baseline visit. Safety analysis included data collected through 23 August 2021 in BRAVE-AA1 and 30 August 2021 in BRAVE-AA2. Safety findings thus reflect data collected beyond 52 weeks, with up to 128 weeks in BRAVE-AA1 and 108 weeks in BRAVE-AA2. Incidence rates (IRs) were calculated based on time at risk for a patient with an event.

3 Results

3.1 Patients

Among patients randomized at baseline to baricitinib 4 mg and 2 mg, respectively, 252/281 (89.7%) and 163/184

(88.6%) in BRAVE-AA1 and 209/234 (89.3%) and 134/156 (85.9%) in BRAVE-AA2 completed 52 weeks of study treatment (ESM Fig. S1). The most common reasons for discontinuation in BRAVE-AA1 and BRAVE-AA2 were patient withdrawal ($n = 21$ and $n = 21$, respectively), AEs ($n = 8$ and $n = 11$, respectively), and loss to follow-up ($n = 11$ and $n = 9$, respectively).

Baseline characteristics were comparable across baricitinib groups in both trials (Table 1). For patients randomized to baricitinib in BRAVE-AA1 and BRAVE-AA2, respectively, mean age was 37.0 and 38.4 years, 58.9% and 63.3% were female, and mean SALT scores at baseline were 85.9 and 85.1. For ClinRO Measures for Eyebrow Hair Loss and Eyelash Hair Loss, respectively, 69.7% and 59.8% in BRAVE-AA1 and 67.9% and 58.7% in BRAVE-AA2 had scores of 2 or 3 (significant gaps or no notable hair) at baseline.

3.2 Efficacy

The proportions of patients achieving SALT score ≤ 20 continuously increased over the treatment period, with response rates for patients treated with baricitinib 4 mg and 2 mg, respectively, reaching 40.9% and 21.2% in BRAVE-AA1 and 36.8% and 24.4% in BRAVE-AA2 at Week 52 (Fig. 1, ESM Table S1). Among patients with severe baseline disease (SALT score 50–94) treated with baricitinib 4 mg and 2 mg, respectively, a SALT score ≤ 20 was achieved in 55.6% and 36.4% in BRAVE-AA1 and 46.1% and 35.7% in BRAVE-AA2. Among patients with very severe disease at baseline (SALT score 95–100) in the baricitinib 4 mg and 2 mg groups, respectively, 27.7% and 10.3% in BRAVE-AA1 and 27.7% and 15.1% in BRAVE-AA2 achieved a SALT score ≤ 20 .

In the baricitinib 4 mg and 2 mg groups, respectively, 29.9% and 14.1% in BRAVE-AA1 and 27.8% and 16.7% in BRAVE-AA2 achieved a SALT score ≤ 10 (ESM Table S1). With the baricitinib 4 mg and 2 mg doses, respectively, SALT₅₀ was achieved at Week 52 in 52.0% and 31.0% in BRAVE-AA1 and 52.6% and 37.2% in BRAVE-AA2; 28.5% and 11.4% in BRAVE-AA1 and 26.1% and 14.1% in BRAVE-AA2 achieved SALT₉₀ at Week 52 (ESM Table S1). Representative photographs of patients who responded to baricitinib in BRAVE-AA1 are presented in Fig. 2.

Eyebrow and eyelash response rates also increased over the 52-week period. Among patients with ClinRO Measure for Eyebrow Hair Loss baseline scores of 2 or 3 who were treated with baricitinib 4 mg and 2 mg, respectively, 39.4% and 27.9% in BRAVE-AA1 and 49.7% and 16.3% in BRAVE-AA2 improved ≥ 2 points and scored 0 or 1 at Week 52 (Fig. 3, ESM Table S1). Of those with ClinRO

Table 1 Baseline demographics and clinical characteristics

Characteristic	BRAVE-AA1		BRAVE-AA2	
	Baricitinib 2 mg [N = 184]	Baricitinib 4 mg [N = 281]	Baricitinib 2 mg [N = 156]	Baricitinib 4 mg [N = 234]
Age, years [mean (SD)]	38.0 (12.8)	36.3 (13.3)	39.0 (13.0)	38.0 (12.7)
Female	109 (59.2)	165 (58.7)	103 (66.0)	144 (61.5)
Race ^a				
White	93 (50.8)	123 (43.9)	92 (59.0)	144 (61.5)
Asian	76 (41.5)	114 (40.7)	49 (31.4)	67 (28.6)
Black or African American	7 (3.8)	28 (10.0)	12 (7.7)	18 (7.7)
Other	7 (3.8)	15 (5.4)	3 (1.9)	5 (2.1)
Geographic region ^b				
North America	102 (55.4)	153 (54.4)	54 (34.6)	82 (35.0)
Asia	70 (38.0)	107 (38.1)	42 (26.9)	63 (26.9)
Rest of world	12 (6.5)	21 (7.5)	60 (38.5)	89 (38.0)
Duration since AA onset, years [mean (SD)]	12.1 (9.8)	11.8 (11.1)	13.1 (11.8)	11.9 (11.1)
Duration of current episode of AA, years [mean (SD)]	3.9 (4.7)	3.5 (3.4)	4.4 (6.1)	3.9 (3.4)
< 4 years	127 (69.0)	189 (67.3)	103 (66.0)	140 (59.8)
≥ 4 years	57 (31.0)	92 (32.7)	53 (34.0)	94 (40.2)
Proportion of patients with alopecia universalis ^c	83 (45.1)	127 (45.2)	70 (44.9)	111 (47.4)
Proportion of patients with atopic background ^d	67 (36.4)	97 (34.5)	63 (40.4)	87 (37.2)
Weight, kg [mean (SD)]	74.3 (17.8)	74.7 (17.0)	72.3 (16.1)	74.0 (15.7)
Body mass index [mean (SD)]	26.0 (5.4)	26.4 (5.5)	26.2 (5.1)	26.4 (4.9)
SALT score [mean (SD)]	86.8 (18.0)	85.3 (18.2)	85.6 (18.1)	84.8 (18.1)
SALT score [median]	99.0	96.0	97.0	95.0
Severity				
Severe (SALT score 50–94)	77 (41.8)	133 (47.3)	70 (44.9)	115 (49.1)
Very severe (SALT score 95–100)	107 (58.2)	148 (52.7)	86 (55.1)	119 (50.9)
ClinRO Measure for Eyebrow Hair Loss™ score of 2 or 3 ^e	136 (73.9)	188 (67.6)	104 (66.7)	161 (69.1)
ClinRO Measure for Eyelash Hair Loss™ score of 2 or 3 ^e	111 (60.3)	167 (60.1)	89 (57.1)	140 (60.1)

Data are expressed as *n* (%) unless otherwise specified

Percentages are for non-missing values

AA alopecia areata, *ClinRO* clinician-reported outcome, *n* number of patients in the specified category, *N* total population size, *SALT* Severity of Alopecia Tool, *SD* standard deviation

^a‘Other’ includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, or multiple races

^bGeographic regions for BRAVE-AA1 include Asia (South Korea) and rest of world (Mexico), and for BRAVE-AA2 include Asia (South Korea, Japan, Taiwan, China) and rest of world (Israel, Australia, Brazil, Argentina). North America in both studies includes the United States

^cDiagnosis of alopecia universalis was according to the investigator’s assessment

^dAtopic background is defined as medical history or current atopic dermatitis, allergic rhinitis, allergic conjunctivitis, or allergic asthma

^eA ClinRO score of 2 indicates significant gaps in eyebrow(s)/eyelashes, and a score of 3 indicates no notable eyebrow(s)/eyelashes

Measure for Eyelash Hair Loss baseline scores of 2 or 3 in the baricitinib 4 mg and 2 mg groups, respectively, 40.7% and 21.6% in BRAVE-AA1 and 50.7% and 30.3% in BRAVE-AA2 had ≥ 2-point improvements and achieved scores of 0 or 1 at Week 52 (Fig. 4, ESM Table S1).

Results of the post hoc analysis of efficacy outcomes using multiple imputation for missing data are reported in ESM Figs. S2–S4 and ESM Table S2.

3.3 Safety

A total of 280 (patient-years exposure [PYE] = 385.5) and 183 (PYE = 197.9) patients in BRAVE-AA1 and 233 (PYE = 284.8) and 155 (PYE = 168.7) patients in BRAVE-AA2 were exposed to baricitinib 4 mg and 2 mg, respectively. Among patients in the baricitinib 4 mg and 2 mg groups, respectively, treatment-emergent AEs (TEAEs) were reported




Fig. 1 Proportions of patients achieving SALT score ≤ 20 through Week 52 in **a** BRAVE-AA1 and **b** BRAVE-AA2. A SALT score ≤ 20 indicates $\leq 20\%$ scalp hair loss. Bars represent 95% confidence inter-

vals. Non-responder imputation was applied to missing data (prespecified analysis). Week-36 data points reflect results from the placebo-controlled period. *SALT* Severity of Alopecia Tool



Fig. 2 Clinical photographs of patients with alopecia areata at baseline and after 36 weeks and 52 weeks of treatment with baricitinib 4 mg in BRAVE-AA1. SALT scores indicate percentage of scalp hair

loss as assessed by the investigator. Patient images ©Eli Lilly and Company. *SALT* Severity of Alopecia Tool

in 69.6% (IR = 110.8) and 58.5% (IR = 94.5) in BRAVE-AA1 and 77.3% (IR = 159.1) and 74.2% (IR = 168.7) in BRAVE-AA2 (Table 2). Most TEAEs were mild or moderate in severity. The most frequently reported TEAEs were upper respiratory tract infection, headache, nasopharyngitis, acne, urinary tract infection, increased blood creatinine phosphokinase (CPK), and COVID-19 infection (Table 2). There were no patterns in types of SAEs; the most common SAEs were bone fractures due to injury (ESM Table S3). The frequency of discontinuations due to AEs was low and similar across groups (ESM Table S4).

AEs during the 36-week placebo-controlled period have been previously reported [1]. Newly reported herpes zoster infections that occurred after the placebo-controlled period were localized; all patients recovered, and none discontinued. Herpes simplex infections were all mild or moderate and there were no discontinuations. After the placebo-controlled period,

serious infections during the extension phase of BRAVE-AA2 included one (0.4%, IR = 0.3) case each of appendicitis, herpes zoster, and COVID-19 with baricitinib 4 mg; all patients recovered, and none discontinued (ESM Table S3). During the extension period of BRAVE-AA2, one (0.4%, IR = 0.3) COVID-19 infection with baricitinib 4 mg led to study discontinuation. No serious infections or infections leading to discontinuation were reported in BRAVE-AA1. Malignancies reported during the trial extension periods included one (0.5%, IR = 0.5) squamous cell carcinoma after 16 months with baricitinib 2 mg, and one (0.4%, IR = 0.3) ductal carcinoma in situ after 10 months with baricitinib 4 mg in BRAVE-AA1; the latter patient discontinued per protocol. No VTEs, opportunistic infections, cases of tuberculosis, gastrointestinal perforations, or deaths were reported in either trial over the observation period (Table 2).




Fig. 3 Proportion of patients achieving ClinRO Measure for Eyebrow Hair Loss™ 0 or 1 with ≥ 2 -point improvement from baseline through Week 52 among patients with a score of ≥ 2 at baseline in **a** BRAVE-AA1 and **b** BRAVE-AA2. A ClinRO score of 0 indicates full coverage and a score of 1 indicates minimal gaps in eyebrows.

Bars represent 95% confidence intervals. Non-responder imputation was applied to missing data (prespecified analysis). Week-36 data points reflect results from the placebo-controlled period. *ClinRO* Clinician-Reported Outcome




Fig. 4 Proportion of patients achieving ClinRO Measure for Eyelash Hair Loss™ 0 or 1 with ≥ 2 -point improvement from baseline through Week 52 among patients with a score of ≥ 2 at baseline in **a** BRAVE-AA1 and **b** BRAVE-AA2. A ClinRO score of 0 indicates full coverage and a score of 1 indicates minimal gaps in eyelashes.

Bars represent 95% confidence intervals. Non-responder imputation was applied to missing data (prespecified analysis). Week-36 data points reflect results from the placebo-controlled period. *ClinRO* Clinician-Reported Outcome

Most laboratory changes were balanced across baricitinib groups in both studies. Increases in CPK, low-density lipoprotein, and high-density lipoprotein were more frequent with the 4 mg dose (Table 3). CPK increases were mostly Common Terminology Criteria for Adverse Events (CTCAE) [8] grade 1 or 2, and there were no cases of rhabdomyolysis. CTCAE grade 4 neutropenia (neutrophils < 0.5 billion/L) was seen in one baricitinib 4 mg patient in the extension period of BRAVE-AA1; the patient recovered and continued the study. During the trial extension periods, thrombocytosis (platelets > 600 billion/L) occurred in one patient with baricitinib 4 mg in BRAVE-AA1 and one patient with baricitinib 2 mg in BRAVE-AA2; both patients

recovered and continued the study. Frequencies of hepatic test abnormalities were consistent with those previously reported [1] and were not associated with TEAEs leading to study drug interruption or discontinuation.

4 Discussion

In BRAVE-AA1 and BRAVE-AA2, response rates in scalp hair regrowth increased over 52 weeks of baricitinib treatment in adults with severe AA, with 40.9% and 36.8%, respectively, of baricitinib 4 mg-treated patients achieving a SALT score ≤ 20 at Week 52. Eyebrow and eyelash

Table 2 Summary of safety outcomes

	BRAVE-AA1		BRAVE-AA2	
	Baricitinib 2 mg [<i>N</i> = 183]	Baricitinib 4 mg [<i>N</i> = 280]	Baricitinib 2 mg [<i>N</i> = 155]	Baricitinib 4 mg [<i>N</i> = 233]
Any TEAE	107 (58.5) [94.5]	195 (69.6) [110.8]	115 (74.2) [168.7]	180 (77.3) [159.1]
TEAE severity ^a				
Mild	59 (32.2) [36.9]	101 (36.1) [35.6]	57 (36.8) [45.7]	90 (38.6) [42.2]
Moderate	43 (23.5) [24.6]	81 (28.9) [24.4]	54 (34.8) [39.4]	73 (31.3) [32.2]
Severe	5 (2.7) [2.4]	13 (4.6) [3.3]	4 (2.6) [2.3]	17 (7.3) [5.9]
Serious AE	5 (2.7) [2.4]	11 (3.9) [2.8]	4 (2.6) [2.3]	13 (5.6) [4.5]
Death	0	0	0	0
AE leading to study drug discontinuation	4 (2.2) [1.9]	8 (2.9) [2.0]	4 (2.6) [2.3]	10 (4.3) [3.4]
TEAEs occurring in ≥ 5% of patients in any group				
Upper respiratory tract infection	12 (6.6) [6.0]	24 (8.6) [6.5]	17 (11.0) [10.3]	20 (8.6) [7.2]
Headache	11 (6.0) [5.4]	18 (6.4) [4.8]	15 (9.7) [9.0]	29 (12.4) [10.6]
Nasopharyngitis	13 (7.1) [6.5]	23 (8.2) [6.2]	5 (3.2) [2.8]	20 (8.6) [7.2]
Acne	13 (7.1) [6.5]	19 (6.8) [5.1]	9 (5.8) [5.4]	13 (5.6) [4.6]
Urinary tract infection	5 (2.7) [2.4]	13 (4.6) [3.4]	16 (10.3) [9.6]	14 (6.0) [4.9]
Blood creatine phosphokinase increased	3 (1.6) [1.4]	26 (9.3) [6.9]	0	8 (3.4) [2.8]
COVID-19 infection	3 (1.6) [1.4]	6 (2.1) [1.5]	4 (2.6) [2.3]	13 (5.6) [4.5]
Infectious AEs				
At least one treatment-emergent infection	57 (31.1) [35.7]	111 (39.6) [39.9]	75 (48.4) [65.5]	101 (43.3) [49.9]
Serious infection	0	0	2 (1.3) [1.1]	4 (1.7) [1.4]
Opportunistic infection	0	0	0	0
Herpes zoster	2 (1.1) [1.0]	2 (0.7) [0.5]	6 (3.9) [3.4]	8 (3.4) [2.7]
Herpes simplex	1 (0.5) [0.5]	9 (3.2) [2.3]	7 (4.5) [4.1]	4 (1.7) [1.4]
Tuberculosis	0	0	0	0
Infections leading to study treatment discontinuation	0	0	1 (0.6) [0.6]	1 (0.4) [0.3]
AEs of special interest				
Major adverse cardiovascular event	1 (0.5) [0.5] ^b	0	0	0
Venous thromboembolism	0	0	0	0
Malignancies other than non-melanoma skin cancer	0	1 (0.4) [0.3] ^c	0	1 (0.4) [0.3] ^d
Non-melanoma skin cancer	1 (0.5) [0.5] ^e	0	0	0
Gastrointestinal perforations	0	0	0	0

Data are expressed as *n* (%) [IR]

AE adverse event, COVID-19 coronavirus disease 2019, IR incidence rate, *n* number of patients in the specified category, *N* number of patients in the analysis set, TEAE treatment-emergent adverse event

^aPatients with multiple occurrences of the same event are counted under the highest severity

^bMyocardial infarction in a patient with multiple risk factors, including current tobacco use, obesity, atrial fibrillation, hypertension, and a history of hypercholesterolemia. This was reported during the placebo-controlled period and occurred after approximately 9 months of treatment (also adjudicated as arterial thromboembolism) [1]

^cDuctal carcinoma in situ diagnosed after approximately 10 months of treatment

^dB-cell lymphoma diagnosed after approximately 4 months of treatment and reported during the placebo-controlled period

^eSquamous cell carcinoma diagnosed after approximately 16 months of treatment

response rates also increased over time, indicating that long-term treatment may be required to observe maximum clinical benefit. In both studies, numerically greater proportions of patients achieved efficacy endpoints with baricitinib 4 mg versus 2 mg, and these differences were sustained over time.

No new safety signals were observed versus the 36-week placebo-controlled period [1]. The most common AEs included upper respiratory tract infection, headache, nasopharyngitis, acne, urinary tract infection, CPK elevation, and COVID-19 infection. The frequency of COVID-19 infections reflects the evolution of the COVID-19 pandemic during the

Table 3 Summary of laboratory changes

	BRAVE-AA1		BRAVE-AA2	
	Baricitinib 2 mg [N = 183]	Baricitinib 4 mg [N = 280]	Baricitinib 2 mg [N = 155]	Baricitinib 4 mg [N = 233]
Anemia CTCAE grade ≥ 3 (hemoglobin < 4.9 mmol/L)	0	1 (0.4)	0	1 (0.4)
Neutrophils CTCAE grade ≥ 3 (< 1.0 billion/L)	1 (0.6)	3 (1.1)	2 (1.3)	5 (2.2)
Lymphocytes CTCAE grade ≥ 3 (< 0.5 billion/L)	0	1 (0.4)	0	2 (0.9)
Leukocytes CTCAE grade ≥ 3 (< 2.0 billion/L)	0	0	0	0
Thrombocytosis (platelets > 600 billion/L)	1 (0.6)	3 (1.1)	1 (0.7)	0
ALT $\geq 3 \times$ ULN	4 (2.2)	9 (3.2)	6 (3.9)	7 (3.0)
AST $\geq 3 \times$ ULN	6 (3.3)	8 (2.9)	1 (0.6)	6 (2.6)
TBL $\geq 2 \times$ ULN	0	5 (1.8)	0	2 (0.9)
ALP $\geq 1.5 \times$ ULN	4 (2.2)	1 (0.4)	3 (1.9)	1 (0.4)
CPK CTCAE grade ≥ 3 ($> 5 \times$ ULN) ^a	6 (3.3)	26 (9.5)	4 (2.6)	16 (7.0)
LDL ≥ 3.36 mmol/L ^b	31 (23.5)	80 (38.6)	37 (33.3)	63 (35.4)
HDL ≥ 1.55 mmol/L ^c	43 (44.3)	81 (49.7)	33 (37.5)	63 (46.7)
Triglycerides ≥ 5.65 mmol/L ^d	2 (1.2)	5 (1.9)	0	0

Data are expressed as n (%)

Percentages are based on number of patients at risk for the specified anomaly

ALP alkaline phosphatase, ALT alanine transaminase, AST aspartate transaminase, CPK creatine phosphokinase, CTCAE Common Terminology Criteria for Adverse Events, HDL high-density lipoprotein, LDL low-density lipoprotein, n number of patients in the specified category, N number of patients in the analysis, NCEP National Cholesterol Education Program, TBL total bilirubin, ULN upper limit of normal

^aThere were no associated cases of rhabdomyolysis

^bIncrease to borderline high, high, or very high (NCEP criteria)

^cIncrease to high (NCEP criteria)

^dIncrease to very high (NCEP criteria)

conduct of the trials. No VTEs were reported in either study. Newly reported malignancies included one case each of squamous cell carcinoma and ductal carcinoma in situ. Long-term safety data in rheumatoid arthritis do not suggest increased incidence of malignancies with baricitinib [9], but longer-term data are needed in AA to assess causal associations. Most increases in CPK to ≥ 5 times the upper limit of normal in baricitinib-treated patients were related to physical exercise, and no cases of rhabdomyolysis were reported.

As most patients randomized to placebo at baseline were non-responders (SALT score > 20) at Week 36 [1], they were switched to treatment with baricitinib at Week 36. Thus, there were no statistical comparisons with placebo in the present analysis. Both trials excluded patients who had current episodes lasting ≥ 8 years without any hair regrowth and patients with previous inadequate response to JAK inhibitors. Thus, efficacy in these patients remains to be established. Due to the COVID-19 pandemic, some assessments were missed or performed remotely and censored. As this may lead to an underestimation of efficacy values, analyses using multiple imputation are provided in the ESM.

Response rates for most endpoints did not plateau over the study period, indicating that maximum benefit in scalp,

eyebrow, and eyelash hair regrowth may require more than 52 weeks of treatment, in particular for patients with more extensive disease. The present analysis demonstrates the benefits of continuous baricitinib treatment over 1 year for severe AA; however, longer periods of observation are required to evaluate the full extent and stability of clinical response. BRAVE-AA1 and BRAVE-AA2 are ongoing and will follow patients for up to 200 weeks. Eligible patients entered randomized withdrawal or downtitration at Week 52 to assess the durability of clinical response and long-term safety, and these data will be reported in future publications.

5 Conclusions

In two independent phase III trials of adults with severe AA, the proportions of patients achieving scalp hair, eyebrow, and eyelash regrowth increased over 52 weeks of treatment with once-daily oral baricitinib. Clinical response was numerically greater with baricitinib 4 mg than 2 mg. Safety findings were consistent with the known safety profile of baricitinib. These results confirm the potential for baricitinib in the treatment of severe AA.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s40257-023-00764-w>.

Acknowledgments The authors would like to thank the clinical trial participants and their caregivers, without whom this work would not be possible, as well as all investigators and study staff who participated in these trials. Medical writing and editorial support were provided by Amy K. Ellinwood, PhD, of Eli Lilly and Company. Results were presented in part at the American Academy of Dermatology Annual Meeting in March 2022.

Declarations

Funding This study was sponsored by Eli Lilly and Company (Lilly), under license from Incyte Corporation.

Competing Interests Ohsang Kwon reports grants from Lilly during the conduct of the study and grants from Pfizer, Amorepacific Corporation and Jovic Co., and personal fees from Yuhan Pharmaceuticals outside the submitted work. Maryanne M. Senna has served on scientific advisory boards for Lilly, Pfizer, Concert, Arena, Follica, Deciphera, Cassiopea; as a speaker for Lilly & Pfizer; and as principal investigator (PI) for Lilly and Concert. Rodney Sinclair is a member of the Lilly advisory board and was PI in the Lilly-sponsored BRAVE clinical trials. Taisuke Ito has served on advisory boards and/or is a consultant and/or clinical trial investigator for Bristol-Myers Squibb, Lilly, Pfizer, Regeneron, and Maruho Co Ltd. Brett King has served on advisory boards and/or is a consultant and/or clinical trial investigator for AbbVie, AltruBio Inc., Almirall, AnaptysBio, Arena, Bioniz Therapeutics, Bristol-Myers Squibb, Concert, Horizon Therapeutics, Lilly, Incyte, LEO Pharma, Otsuka/Visterra Inc., Pfizer, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc., and Viela Bio. He is on speaker bureaus for AbbVie, Incyte, Lilly, Pfizer, Regeneron, and Sanofi Genzyme. Yves Dutronc, Guanglei Yu, Chiara Chiasserini, Jill McCollam, and Wen-Shuo Wu are employees and shareholders of Lilly. Chen-Yen Lin was an employee of Lilly during the period the studies were conducted.

Authorship Each author has met the authorship criteria established by the International Committee of Medical Journal Editors. All authors contributed to study design and data interpretation. Statistical analysis was performed by GY and CL. All authors contributed to writing and reviewing the manuscript, and all authors read and approved the final manuscript.

Data Availability Lilly provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the US and EU and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org.

Ethics Approval The trials were performed in accordance with ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The research protocols were approved by each center's IRB or Ethics Committee; BRAVE-AA1 was first approved by Advarra IRB on 13 August 2018,

and BRAVE-AA2 was first approved by Quorum Review IRB on 19 February 2019

Patient Consent to Participate Written informed consent was obtained from all individual participants included in the study.

Patient Consent to Publish Patients signed informed consent regarding publishing their data and photographs.

Code Availability Not applicable.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

References

1. King B, Ohshima M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. two phase 3 trials of baricitinib for alopecia areata. *N Engl J Med*. 2022;386(18):1687–99.
2. Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol*. 2019;33(5):850–6.
3. Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. *J Am Acad Dermatol*. 2017;76(4):736–44.
4. Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. *Nat Med*. 2014;20(9):1043–9.
5. Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, et al. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. *Br J Dermatol*. 2020;183(4):702–9.
6. Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines—Part II. National Alopecia Areata Foundation. *J Am Acad Dermatol*. 2004;51(3):440–7.
7. Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, et al. Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata. *Am J Clin Dermatol*. 2020;21(5):725–32.
8. Common Terminology Criteria for Adverse Events. Version 5.0. Published 27 November 2017. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2020.
9. Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. *Ann Rheum Dis*. 2022;81(3):335–43.